Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …

Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for
patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides …

Secondary hypogammaglobulinemia (SHG) is characterized by reduced immunoglobulin
levels due to acquired causes of decreased antibody production or increased antibody loss …

Ibrutinib has revolutionized the management of chronic lymphocytic leukemia and is now
being increasingly used. Although considered to be less immunosuppressive than …

Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies.
Primary antibody deficiency (PAD) is the result of intrinsic genetic defects, whereas …

The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were
evaluated in a phase 2 study; 51 patients had TP53 aberration (TP53 cohort) and 35 were …

A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since
the time clinical staging was introduced in clinical practice in 1975. Over the years, the …